Publications by authors named "Donald Banerji"

Claim this Profile
E
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients.
Konstantinos Kostikas, Alexander J Mackay, Claus F Vogelmeier, Stefan-Marian Frent, Pritam Gupta, Donald Banerji

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Alexander J Mackay, Konstantinos Kostikas, Nicolas Roche, Stefan-Marian Frent, Petter Olsson, Donald Banerji

Respir Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Stefan M Frent, Kenneth R Chapman, Michael Larbig, Alexander Mackay, Robert Fogel, Donald Banerji

Am J Respir Crit Care Med· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Claus F Vogelmeier, Kenneth R Chapman, Marc Miravitlles, Nicolas Roche, Jørgen Vestbo, Donald Banerji

Int J Chron Obstruct Pulmon Dis· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease Exacerbations.
Alex J Mackay, Konstantinos Kostikas, Lindsey Murray, Fernando J Martinez, Marc Miravitlles, Donald Banerji

Am J Respir Crit Care Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Kenneth R Chapman, John R Hurst, Stefan-Marian Frent, Michael Larbig, Robert Fogel, Donald Banerji

Am J Respir Crit Care Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
Jadwiga A Wedzicha, Donald Banerji, Konstantinos Kostikas

N Engl J Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Antonio R Anzueto, Konstantinos Kostikas, Karen Mezzi, Steven Shen, Michael Larbig, Donald Banerji

Respir Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.
Alberto Papi, Konstantinos Kostikas, Jadwiga A Wedzicha, Claus F Vogelmeier, Nicolas Roche, Donald Banerji

Am J Respir Crit Care Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Donald Banerji

Am J Respir Crit Care Med· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease.
James F Donohue, Paul W Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji

Pulm Pharmacol Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Antonio R Anzueto, Claus F Vogelmeier, Konstantinos Kostikas, Karen Mezzi, Sebastian Fucile, Donald Banerji

Int J Chron Obstruct Pulmon Dis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Donald Banerji, Robert Fogel, Francesco Patalano

Drug Discov Today· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Edward Kerwin, Gary T Ferguson, Shahin Sanjar, Thomas Goodin, Anthony Yadao, Donald Banerji

Lung· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Donald Banerji

Am J Respir Crit Care Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Jadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, Michael Humphries, Robert Fogel, Donald Banerji

Int J Chron Obstruct Pulmon Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Shu Hashimoto, Hisataro Ikeuchi, Shujiro Murata, Tetsuji Kitawaki, Kimitoshi Ikeda, Donald Banerji

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Claus Vogelmeier, Nanshan Zhong, Michael J Humphries, Karen Mezzi, Robert Fogel, Donald Banerji

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Ioanna Tsiligianni, Karen Mezzi, Sebastian Fucile, Konstantinos Kostikas, Steven Shen, Donald Banerji

COPD· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial.
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Donald Banerji

Am J Respir Crit Care Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Nanshan Zhong, Changzheng Wang, Xiangdong Zhou, Nuofu Zhang, Michael Humphries, Donald Banerji

COPD· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE.
Kazuhisa Asai, Kazuto Hirata, Shu Hashimoto, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Donald Banerji

Respir Investig· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol-Glycopyrronium for COPD.
Jadwiga A Wedzicha, Donald Banerji, Claus F Vogelmeier

N Engl J Med· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.
Gary T Ferguson, Angel Fowler Taylor, Chau Thach, Qian Wang, Agnes A Schubert-Tennigkeit, Donald Banerji

Chronic Obstr Pulm Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
Donald Banerji, Donald A Mahler, Nicola A Hanania

Expert Rev Respir Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis